Mani Foroohar, MD, senior managing director, Genetic Medicines, and a senior research analyst with SVB Securities wrote in research notes last week that both gene therapies represented relatively small market opportunities for Bluebird. SVB’s model projects $64 million in peak annual sales for beti-cel and $38 million for eli-cel. Foroohar maintained SVB’s “Market Perform” rating on Bluebird shares. “Small but much needed win for BLUE,” Foroohar wrote of eli-cel’s approval on June 10 . . .